Literature DB >> 12856120

The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis.

Christian Brun-Buisson1, Françoise Roudot-Thoraval, Emmanuelle Girou, Catherine Grenier-Sennelier, Isabelle Durand-Zaleski.   

Abstract

OBJECTIVE: To document the costs and outcomes of the various forms of the septic syndromes [systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock), particularly those associated with infection acquired in an intensive care unit (ICU).
DESIGN: Prospective data collection for all septic patients admitted to a medical ICU during a 1-year period. Costs were computed from the viewpoint of the hospital.
RESULTS: Mean total hospital costs were Euro 26,256, Euro 35,185, and Euro 27,083 for patients with sepsis, severe sepsis, and septic shock, respectively. Total costs varied slightly according to the site of infection and the severity of sepsis but were influenced mostly by its mode of acquisition: patients having sepsis associated with ICU-acquired infection incurred total costs about three times those of patients presenting with infection and sepsis on ICU admission (from Euro 39,908 in patients with ICU acquired sepsis to Euro 44,851 in patients with ICU-acquired septic shock). Stratifying patients by the presence of ICU-acquired infection also showed that a first episode of infection complicated by ICU-acquired sepsis incurred at least 2.5 times more costs than a single episode of sepsis.
CONCLUSIONS: In this series the medical costs of sepsis were not markedly influenced by its severity but by its mode of acquisition. Due to wide variations in ICU costs cost-effectiveness analyses of treatments for sepsis should document the case-mix of patients and the contribution to this of nosocomial infections.

Entities:  

Mesh:

Year:  2003        PMID: 12856120     DOI: 10.1007/s00134-003-1877-x

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  26 in total

1.  The economic impact of HA-1A (Centoxin) against endotoxin.

Authors:  S L Barriere
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

2.  The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.

Authors:  P K Linden; D C Angus; L Chelluri; R A Branch
Journal:  J Crit Care       Date:  1995-12       Impact factor: 3.425

3.  Research without billing data. Econometric estimation of patient-specific costs.

Authors:  P G Barnett
Journal:  Med Care       Date:  1997-06       Impact factor: 2.983

4.  Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit.

Authors:  C Chaix; I Durand-Zaleski; C Alberti; C Brun-Buisson
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

5.  Evaluation of definitions for sepsis.

Authors:  W A Knaus; X Sun; O Nystrom; D P Wagner
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

6.  Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.

Authors:  D Pittet; D Tarara; R P Wenzel
Journal:  JAMA       Date:  1994-05-25       Impact factor: 56.272

7.  Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group.

Authors:  C Brun-Buisson; F Doyon; J Carlet
Journal:  Am J Respir Crit Care Med       Date:  1996-09       Impact factor: 21.405

Review 8.  Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients.

Authors:  B E Kreger; D E Craven; P C Carling; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

9.  Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients.

Authors:  D Pittet; B Thiévent; R P Wenzel; N Li; R Auckenthaler; P M Suter
Journal:  Am J Respir Crit Care Med       Date:  1996-02       Impact factor: 21.405

10.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis.

Authors:  C Brun-Buisson; F Doyon; J Carlet; P Dellamonica; F Gouin; A Lepoutre; J C Mercier; G Offenstadt; B Régnier
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272

View more
  24 in total

1.  Melatonin augments apoptotic adipose-derived mesenchymal stem cell treatment against sepsis-induced acute lung injury.

Authors:  Hong-Hwa Chen; Chia-Lo Chang; Kun-Chen Lin; Pei-Hsun Sung; Han-Tan Chai; Yen-Yi Zhen; Yi-Ching Chen; Ying-Chung Wu; Steve Leu; Tzu-Hsien Tsai; Chih-Hung Chen; Hsueh-Wen Chang; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  Year in review in Intensive Care Medicine-2003. Part 1: Respiratory failure, infection and sepsis.

Authors:  Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoît Vallet
Journal:  Intensive Care Med       Date:  2004-05-15       Impact factor: 17.440

Review 3.  The Economic and Humanistic Burden of Severe Sepsis.

Authors:  Bogdan Tiru; Ernest K DiNino; Abigail Orenstein; Patrick T Mailloux; Adam Pesaturo; Abhinav Gupta; William T McGee
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

Review 4.  [Sepsis. Update on pathophysiology, diagnostics and therapy].

Authors:  M Bauer; F Brunkhorst; T Welte; H Gerlach; K Reinhart
Journal:  Anaesthesist       Date:  2006-08       Impact factor: 1.041

5.  Colonization of the medial lumen is a risk factor for catheter-related bloodstream infection.

Authors:  Josep-Maria Sirvent; Loreto Vidaur; María García; Patricia Ortiz; Jordi de Batlle; Montserrat Motjé; Alfons Bonet
Journal:  Intensive Care Med       Date:  2006-06-29       Impact factor: 17.440

Review 6.  Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes.

Authors:  Greg S Martin
Journal:  Expert Rev Anti Infect Ther       Date:  2012-06       Impact factor: 5.091

7.  The cyclopentenone prostaglandin 15-deoxydelta(12,14)-prostaglandin J2 attenuates the development of zymosan-induced shock.

Authors:  Stefania Marzocco; Rosanna Di Paola; Emanuela Mazzon; Tiziana Genovese; Domenico Britti; Aldo Pinto; Giuseppina Autore; Salvatore Cuzzocrea
Journal:  Intensive Care Med       Date:  2005-03-15       Impact factor: 17.440

8.  Heterogeneous models for an early discrimination between sepsis and non-infective SIRS in medical ward patients: a pilot study.

Authors:  Filippo Mearelli; Nicola Fiotti; Nicola Altamura; Michela Zanetti; Giovanni Fernandes; Ismet Burekovic; Alessandro Occhipinti; Daniele Orso; Carlo Giansante; Chiara Casarsa; Gianni Biolo
Journal:  Intern Emerg Med       Date:  2013-12-22       Impact factor: 3.397

Review 9.  Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony.

Authors:  Guillaume Monneret; Fabienne Venet; Alexandre Pachot; Alain Lepape
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

10.  A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units.

Authors:  Ana M C Sogayar; Flavia R Machado; Alvaro Rea-Neto; Amselmo Dornas; Cintia M C Grion; Suzana M A Lobo; Bernardo R Tura; Carla L O Silva; Ruy G R Cal; Idal Beer; Vilto Michels; Jorge Safi; Marcia Kayath; Eliezer Silva
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.